With a new month just days away, many investors are likely to be reassessing their portfolios and looking for high-quality opportunities.
For those seeking strong long-term growth potential, a number of ASX 200 shares are standing out from the pack. Here are five shares that analysts think smart investors might want to consider buying in July. They are as follows:
Cochlear Ltd (ASX: COH)
Cochlear is a global leader in implantable hearing solutions. It appears well-placed for growth over the next decade thanks to an ageing population and its world class product portfolio and wide distribution network. And with the ASX 200 share investing heavily in its research and development activities each year, it appears well-positioned to maintain its leadership position long into the future.
UBS has a buy rating and $325.00 price target on Cochlear's shares.
CSL Ltd (ASX: CSL)
Another ASX 200 share for smart investors is CSL. It is one of the largest biotech companies in the world and a stalwart of the ASX 200. CSL specialises in plasma therapies and vaccines and has operations across the globe. And while the company has experienced headwinds in recent periods, its long-term fundamentals remain solid. In fact, analysts believe it is destined to deliver double-digit annual earnings growth for the foreseeable future.
Bell Potter has a buy rating and $305.00 price target on its shares.
NextDC Ltd (ASX: NXT)
As Australia's leading data centre operator, NextDC continues to benefit from the growing demand for cloud computing, data storage, and digital infrastructure. The ASX 200 share is investing heavily in expanding its footprint and has a strong pipeline of capacity to come online in the Asia-Pacific region over the next few years. With structural tailwinds at its back, NextDC offers attractive exposure to the digitisation of the economy.
Macquarie is a fan and has an outperform rating and $22.10 price target on its shares.
ResMed Inc. (ASX: RMD)
Macquarie is also positive on ResMed. It is a global leader in sleep and respiratory care solutions. Its products help treat sleep apnoea and other chronic respiratory conditions, and demand is being supported by rising awareness and increasing diagnosis rates. And with over a billion people estimated to suffer from sleep apnoea, it has a huge growth runway.
Macquarie has an outperform rating and $48.00 price target on its shares.
TechnologyOne Ltd (ASX: TNE)
Finally, TechnologyOne could be an ASX 200 share for smart investors to buy. It is a provider of enterprise software solutions to government and corporate clients. It has delivered consistent earnings growth over the past decade and looks well-placed to continue building on this after transitioning very successfully to a software-as-a-service (SaaS) model.
UBS has a buy rating and $42.20 price target on its shares.
